122 related articles for article (PubMed ID: 12394652)
1. The ratio of plasminogen activator inhibitor type-1 activity to the concentration of plasminogen activator inhibitor type-1 protein in diabetes: adding insult to injury.
Sobel BE; Neimane D; Mack WJ; Hodis HN; Buchanan TA
Coron Artery Dis; 2002 Aug; 13(5):275-81. PubMed ID: 12394652
[TBL] [Abstract][Full Text] [Related]
2. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
[TBL] [Abstract][Full Text] [Related]
3. Increased tissue-type plasminogen activator: a facade in the fibrinolytic system in type 2 diabetes.
Sobel BE; Tilton L; Neimane D; Schnure J
Coron Artery Dis; 2005 Feb; 16(1):31-5. PubMed ID: 15654197
[TBL] [Abstract][Full Text] [Related]
4. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
5. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
[TBL] [Abstract][Full Text] [Related]
6. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
7. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome.
Kulwas A; Lisewska B; Jundziłł W; Ruszkowska B; Drewniak W; Ruprecht Z; Gadomska G; Rość D
Adv Med Sci; 2017 Mar; 62(1):87-91. PubMed ID: 28193577
[TBL] [Abstract][Full Text] [Related]
8. Progressive intermittent claudication is associated with impaired fibrinolysis.
Killewich LA; Gardner AW; Macko RF; Hanna DJ; Goldberg AP; Cox DK; Flinn WR
J Vasc Surg; 1998 Apr; 27(4):645-50. PubMed ID: 9576077
[TBL] [Abstract][Full Text] [Related]
9. Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.
Leiper K; Croll A; Booth NA; Moore NR; Sinclair T; Bennett B
J Clin Pathol; 1994 Mar; 47(3):214-7. PubMed ID: 8163691
[TBL] [Abstract][Full Text] [Related]
10. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
11. A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma--standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease.
Philips M; Juul AG; Selmer J; Lind B; Thorsen S
Thromb Haemost; 1992 Nov; 68(5):486-94. PubMed ID: 1455392
[TBL] [Abstract][Full Text] [Related]
12. Association between Plasma Levels of PAI-1, tPA/PAI-1 Molar Ratio, and Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes Mellitus.
Wang J; Yuan Y; Cai R; Huang R; Tian S; Lin H; Guo D; Wang S
J Alzheimers Dis; 2018; 63(2):835-845. PubMed ID: 29689724
[TBL] [Abstract][Full Text] [Related]
13. Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus.
Testa R; Bonfigli AR; Piantanelli L; Manfrini S; Testa I; Gregorio F
Diabetes Res Clin Pract; 1996 Jul; 33(2):111-8. PubMed ID: 8879966
[TBL] [Abstract][Full Text] [Related]
14. Induction of hepatic tissue-type plasminogen activator and type 1 plasminogen activator-inhibitor gene expressions and appearance of their translation products in the bile following acute liver injury in rats.
Noguchi T; Matsuyama S; Akao M; Hagiwara H; Uno S; Seki T; Ariga T
Thromb Res; 2001 Nov; 104(4):283-91. PubMed ID: 11728530
[TBL] [Abstract][Full Text] [Related]
15. Tissue plasminogen activator and plasminogen activator inhibitors of type 1 and type 2 in the plasma of parturient women.
Uszyński M; Uszyński W; Zekanowska E; Garbacz J; Kielkowski A; Marcinkowski Z
J Perinat Med; 1996; 24(4):339-45. PubMed ID: 8880631
[TBL] [Abstract][Full Text] [Related]
16. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
17. The expression of plasminogen activator system in a rat model of periodontal wound healing.
Xiao Y; Li H; Bunn C; Bartold PM
J Periodontol; 2001 Jul; 72(7):849-57. PubMed ID: 11495131
[TBL] [Abstract][Full Text] [Related]
18. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
Gürlek A; Bayraktar M; Kirazli S
Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors.
Nakashima A; Kobayashi T; Terao T
Gynecol Obstet Invest; 1996; 42(2):95-101. PubMed ID: 8878712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
